FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

106 letters match. Newest first.

  1. Omega Tech Labs LLC

    Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.

    High risk
  2. Genuine Virgin Aloe Corp dba Triderma

    FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.

    High risk
  3. Art of Beauty Company, Inc.

    FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.

    High risk
  4. reBom Co., Ltd.

    reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.

    High risk
  5. Laboratorio Magnachem International

    FDA cited Laboratorio Magnachem for CGMP failures and unapproved, misbranded Broncochem cough/cold drugs after a 2023 inspection.

    High risk
  6. Landy International

    FDA found Landy International’s OTC hand sanitizers adulterated after a 2023 inspection revealed missing testing, unsafe water, and data integrity failures.

    High risk
  7. Aruba Aloe Balm N.V.

    Aruba Aloe Balm N.V. made OTC drugs with methanol-contaminated ethanol and failed CGMP, prompting recall and import alert.

    High risk
  8. Seatex, LLC

    FDA: Seatex made hand sanitizer on equipment also used for floor cleaner and skipped ingredient identity tests.

    High risk
  9. Seatex, LLC

    Seatex, LLC made OTC hand sanitizer drugs with inadequate current good manufacturing practice (CGMP), including shared equipment with industrial chemicals and missing component testing.

    High risk
  10. C&T Dream Co., Ltd.

    C&T Dream failed CGMP (current good manufacturing practice) for its over-the-counter Dry Skin Healing Ointment, including identity testing and process validation.

    High risk
  11. Master Paints & Chemicals Corp.

    FDA warned Master Paints & Chemicals Corp. over inadequate testing and quality oversight for OTC drugs including hand sanitizer.

    High risk
  12. FirstCham Co., Ltd.

    FDA warns FirstCham over current good manufacturing practice violations and misbranding of Soo'Ae hand sanitizing wipes.

    High risk
  13. Betone S.A. de C.V.

    FDA warns Betone S.A. de C.V. over manufacturing violations for OTC antiseptic wipes, including subpotent active and missing glycerin safety tests.

    High risk
  14. Higley Industries, Inc.

    FDA warns Higley Industries over CGMP failures in OTC drug manufacturing, including untested ethanol and glycerin.

    High risk
  15. Cosmetic Specialty Labs, Inc.

    FDA warned Cosmetic Specialty Labs after an inspection found manufacturing failures in OTC drugs and an unlisted product.

    High risk
  16. Native Salts LLC

    FDA warns Native Salts LLC over unapproved, misbranded ammonia smelling-salt stimulant sold as 'N, Native Salts'.

    High risk
  17. Bell International Laboratories, Inc.

    Bell International Laboratories, an OTC drugmaker, was cited for manufacturing rule violations including missing glycerin DEG/EG testing and inadequate quality oversight.

    High risk
  18. Les Importations Herbasanté Inc.

    Canadian contract maker of homeopathic drugs, including children's products, skipped ingredient testing and process validation, FDA says.

    High risk
  19. Glicerinas Industriales, S.A. de C.V.

    FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

    High risk
  20. Woorilife & Health

    Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  21. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  22. Dextrum Laboratories Inc.

    FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

    High risk
  23. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  24. Global Pharma Healthcare Private Limited

    FDA warned Global Pharma Healthcare that non-sterile artificial tears and eye ointment from its India plant were tied to a Pseudomonas outbreak with four deaths.

    High risk
  25. Seoul Cosmetics Co., Ltd.

    FDA warned Seoul Cosmetics, a South Korean drug maker, over poor manufacturing quality and unapproved OTC drugs.

    High risk
  26. Kor-Chem, Inc.

    Kor-Chem, Inc. made OTC hand sanitizer drugs with manufacturing violations, including shared equipment with industrial chemicals and missing identity and microbial testing.

    High risk
  27. Similasan AG

    Similasan AG's ophthalmic drugs are unapproved new drugs and violate CGMP (manufacturing quality rules), FDA says.

    High risk
  28. Lex Inc.

    FDA warns Lex Inc. of Medley, Florida, that its over-the-counter drugs are adulterated because manufacturing rules were not met, including missing toxic-ingredient testing.

    High risk
  29. K. Boeun Pharmaceutical Co., Ltd.

    K. Boeun Pharmaceutical's OTC drugs were cited for CGMP violations, including missing identity tests for DEG/EG-risk components and inadequate quality unit.

    High risk
  30. Denison Pharmaceuticals, LLC

    Denison Pharmaceuticals was cited for manufacturing quality failures, contamination risks, and unapproved infant/homeopathic drugs.

    High risk
  31. Avaria Health & Beauty Corp.

    FDA cites Avaria Health & Beauty for manufacturing-rule violations in OTC drugs, including missing glycerin identity testing and weak quality unit.

    High risk
  32. Tan Alize Kozmetik Ve Temizlik Urunleri

    FDA warns Turkish OTC drug maker Tan Alize over missing glycerin identity testing and a weak quality unit; import alert issued.

    High risk
  33. LCC Ltd.

    LCC Ltd., an OTC drug maker, lacked identity testing for risky ingredients and adequate quality oversight, FDA says.

    High risk
  34. Suhan Aerosol

    Suhan Aerosol, an Indian OTC drug maker, failed to test high-risk ingredients for toxic diethylene/ethylene glycol and lacked quality oversight.

    High risk
  35. Skyline Herbals Private Limited

    FDA warns India's Skyline Herbals after it ignored records requests for OTC drugs including toothpaste; all its drugs hit Import Alert 66-79.

    High risk
  36. Orchid Lifesciences

    FDA warns Orchid Lifesciences over over-the-counter drug testing gaps and weak quality unit.

    High risk
  37. Medgel Private Limited

    FDA cited Medgel Private Limited, an Indian OTC drug maker, for manufacturing violations including poor investigations and data integrity failures.

    High risk
  38. Avlon Industries, Inc.

    FDA warned Avlon Industries that its over-the-counter drug manufacturing broke quality rules, citing missing identity tests for high-risk glycerin/propylene glycol and validation failures.

    High risk
  39. NeilMed Pharmaceuticals Inc.

    FDA warned NeilMed Pharmaceuticals that its OTC drug manufacturing had current good manufacturing practice violations, including missing glycerin identity testing and dirty equipment.

    High risk
  40. Champaklal Maganlal Homeo Pharmacy Private Limited

    FDA says Champaklal Maganlal Homeo Pharmacy's Bebelyn diarrhea and colic products are unapproved new drugs for infants.

    High risk
  41. Drivergent, Inc.

    Drivergent's hand sanitizers had acetaldehyde and acetal above allowed limits, FDA says.

    High risk
  42. Accra-Pac, Inc. dba Voyant Beauty

    Voyant Beauty's Elkhart, Indiana plant made OTC aerosol drugs contaminated with benzene and failed to investigate or test properly.

    High risk
  43. Pharmaplast S.A.E.

    FDA cited Pharmaplast S.A.E. for failing to test drug components, including glycerin and ethanol, for dangerous contaminants.

    High risk
  44. Champaklal Maganlal Homeo Pharmacy Private Limited

    Champaklal Maganlal Homeo Pharmacy failed to test each glycerin lot for identity, including DEG/EG, in OTC and homeopathic drugs.

    High risk
  45. Omega Packaging Corp

    Omega Packaging Corp failed to test hand sanitizer ingredients and validate processes, FDA found.

    High risk
  46. Dunagin Pharmaceuticals Inc. dba Massco Dental

    Dunagin Pharmaceuticals dba Massco Dental made oral drugs with CGMP violations including shared equipment and inadequate component testing.

    High risk
  47. Frenda Corporation

    FDA found Frenda made OTC alcohol and hand sanitizer under insanitary conditions with industrial chemical cross-contamination risk.

    High risk
  48. Profounda, Inc.

    FDA warns Profounda about manufacturing quality failures for over-the-counter drugs, including process validation, stability, water system, and glycerin testing.

    High risk
  49. AG Hair Limited

    FDA warned AG Hair Limited over CGMP failures for hand sanitizer drugs, including inadequate investigations, microbiological controls, and component testing.

    High risk
  50. Shopaax.com

    FDA found sildenafil, the drug in Viagra, undeclared in Shopaax.com's Royal Honey for Him, making it an illegally adulterated food.

    High risk